Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fexofenadine + phenylephrine is an oral pharmaceutical combination of two small molecule drugs—**fexofenadine**, a selective antihistamine (histamine H1 receptor antagonist), and **phenylephrine**, a sympathomimetic decongestant. Fexofenadine works by blocking histamine H1 receptors on effector cells in blood vessels and respiratory tract, thereby inhibiting the actions of endogenous histamine responsible for allergy symptoms[3]. Phenylephrine exerts its effect mainly through stimulation of alpha-adrenergic receptors, leading to vasoconstriction of blood vessels in nasal mucosa, which reduces swelling and congestion[2]. The combination is primarily indicated for relief of allergic symptoms such as sneezing, runny nose, and nasal congestion caused by allergic rhinitis or the common cold[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fexofenadine + phenylephrine.